INMB

INmune Bio (INMB)

About INmune Bio (INMB)

INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.

Details

Daily high
$5.06
Daily low
$4.78
Price at open
$5.02
52 Week High
$14.74
52 Week Low
$4.78
Market cap
112.6M
Dividend yield
0.00%
Volume
185,348
Avg. volume
296,964
P/E ratio
-2.47

INmune Bio News

Details

Daily high
$5.06
Daily low
$4.78
Price at open
$5.02
52 Week High
$14.74
52 Week Low
$4.78
Market cap
112.6M
Dividend yield
0.00%
Volume
185,348
Avg. volume
296,964
P/E ratio
-2.47